Q2 2026 saw 27% revenue growth and strong U.S. performance, with new CDx deals and a joint venture fueling future expansion. Adjusted EBITDA loss improved, guidance was raised, and cash reserves strengthened by a $57.5M offering.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.